Brokerages expect that Antares Pharma, Inc. (NASDAQ:ATRS) will report $14.80 million in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Antares Pharma’s earnings, with the highest sales estimate coming in at $17.30 million and the lowest estimate coming in at $12.11 million. Antares Pharma posted sales of $14.20 million during the same quarter last year, which suggests a positive year-over-year growth rate of 4.2%. The firm is expected to report its next quarterly earnings report on Tuesday, March 13th.

According to Zacks, analysts expect that Antares Pharma will report full-year sales of $14.80 million for the current year, with estimates ranging from $52.58 million to $57.80 million. For the next financial year, analysts forecast that the company will report sales of $78.23 million per share, with estimates ranging from $64.00 million to $105.80 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Antares Pharma.

Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings data on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.03). Antares Pharma had a negative net margin of 32.06% and a negative return on equity of 43.05%. The firm had revenue of $15.10 million during the quarter, compared to the consensus estimate of $14.01 million. The business’s revenue was up 11.9% on a year-over-year basis.

A number of brokerages have recently issued reports on ATRS. HC Wainwright set a $5.00 price objective on shares of Antares Pharma and gave the company a “buy” rating in a research report on Friday, October 13th. Piper Jaffray Companies reissued a “buy” rating on shares of Antares Pharma in a research report on Friday, September 8th. Finally, ValuEngine downgraded shares of Antares Pharma from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. One analyst has rated the stock with a sell rating, three have given a buy rating and two have assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $3.84.

In related news, Director Thomas J. Garrity sold 30,000 shares of Antares Pharma stock in a transaction on Tuesday, October 3rd. The shares were sold at an average price of $3.50, for a total transaction of $105,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Leonard S. Jacob sold 230,000 shares of Antares Pharma stock in a transaction on Monday, October 9th. The shares were sold at an average price of $4.05, for a total transaction of $931,500.00. The disclosure for this sale can be found here. 11.60% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ATRS. Bank of New York Mellon Corp lifted its stake in shares of Antares Pharma by 20.1% during the 1st quarter. Bank of New York Mellon Corp now owns 167,515 shares of the specialty pharmaceutical company’s stock valued at $476,000 after buying an additional 28,029 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Antares Pharma by 4.3% during the 1st quarter. Vanguard Group Inc. now owns 5,619,088 shares of the specialty pharmaceutical company’s stock valued at $15,958,000 after buying an additional 232,349 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Antares Pharma by 4.8% during the 1st quarter. Geode Capital Management LLC now owns 958,234 shares of the specialty pharmaceutical company’s stock valued at $2,721,000 after buying an additional 43,629 shares in the last quarter. Morgan Stanley lifted its stake in shares of Antares Pharma by 153.3% during the 1st quarter. Morgan Stanley now owns 996,113 shares of the specialty pharmaceutical company’s stock valued at $2,829,000 after buying an additional 602,834 shares in the last quarter. Finally, KCG Holdings Inc. lifted its stake in shares of Antares Pharma by 48.8% during the 1st quarter. KCG Holdings Inc. now owns 66,717 shares of the specialty pharmaceutical company’s stock valued at $189,000 after buying an additional 21,881 shares in the last quarter. Institutional investors own 34.67% of the company’s stock.

Shares of Antares Pharma (NASDAQ ATRS) opened at $1.87 on Wednesday. Antares Pharma has a 1 year low of $1.58 and a 1 year high of $4.09. The company has a debt-to-equity ratio of 0.69, a quick ratio of 2.89 and a current ratio of 3.34.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/11/29/14-80-million-in-sales-expected-for-antares-pharma-inc-atrs-this-quarter.html.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Get a free copy of the Zacks research report on Antares Pharma (ATRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.